# Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

> **NCT05188677** · PHASE3 · COMPLETED · sponsor: **Clover Biopharmaceuticals AUS Pty** · enrollment: 1831 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Candidate vaccine, SCB-2019
- **BIOLOGICAL:** Comirnaty Vaccine
- **BIOLOGICAL:** Vaxzevria Vaccine
- **BIOLOGICAL:** CoronaVac Vaccine

## Key facts

- **NCT ID:** NCT05188677
- **Lead sponsor:** Clover Biopharmaceuticals AUS Pty
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-13
- **Primary completion:** 2023-06-06
- **Final completion:** 2023-06-06
- **Target enrollment:** 1831 (ACTUAL)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188677, "Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05188677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*